Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

Gross CC, Ahmetspahic D, Ruck T, Schulte-Mecklenbeck A, Schwarte K, Jörgens S, Scheu S, Windhagen S, Graefe B, Melzer N, Klotz L, Arolt V, Wiendl H, Meuth SG, Alferink J.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e289. eCollection 2016 Dec.

2.

HIV-1 Nef impairs the dynamic of DC/NK crosstalk: different outcome of CD56(dim) and CD56(bright) NK cell subsets.

Quaranta MG, Napolitano A, Sanchez M, Giordani L, Mattioli B, Viora M.

FASEB J. 2007 Aug;21(10):2323-34. Epub 2007 Apr 12.

PMID:
17431094
3.

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S.

J Immunol. 2013 Dec 15;191(12):5867-74. doi: 10.4049/jimmunol.1301926. Epub 2013 Nov 6.

4.

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis.

Lünemann A, Tackenberg B, DeAngelis T, da Silva RB, Messmer B, Vanoaica LD, Miller A, Apatoff B, Lublin FD, Lünemann JD, Münz C.

Int Immunol. 2011 Feb;23(2):139-48. doi: 10.1093/intimm/dxq463. Epub 2011 Jan 6.

5.

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM.

PLoS One. 2012;7(6):e39416. doi: 10.1371/journal.pone.0039416. Epub 2012 Jun 25.

6.

Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.

Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S.

Blood. 2002 Sep 1;100(5):1715-20.

7.

Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells.

Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H; Finnish Multiple Sclerosis and Pregnancy Study Group.

Clin Exp Immunol. 2008 Feb;151(2):235-43. Epub 2007 Dec 6.

8.

Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.

Johnson TA, Evans BL, Durafourt BA, Blain M, Lapierre Y, Bar-Or A, Antel JP.

J Immunol. 2011 Jul 1;187(1):570-9. doi: 10.4049/jimmunol.1003823. Epub 2011 May 27.

9.

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.

Lin YC, Winokur P, Blake A, Wu T, Romm E, Bielekova B.

Ann Clin Transl Neurol. 2015 May;2(5):445-55. doi: 10.1002/acn3.181. Epub 2015 Apr 7.

10.

Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.

Rodríguez-Martín E, Picón C, Costa-Frossard L, Alenda R, Sainz de la Maza S, Roldán E, Espiño M, Villar LM, Álvarez-Cermeño JC.

Clin Exp Immunol. 2015 May;180(2):243-9. doi: 10.1111/cei.12580.

11.

Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.

Havari E, Turner MJ, Campos-Rivera J, Shankara S, Nguyen TH, Roberts B, Siders W, Kaplan JM.

Immunology. 2014 Jan;141(1):123-31. doi: 10.1111/imm.12178.

12.

Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection.

Naranbhai V, Chang CC, Durgiah R, Omarjee S, Lim A, Moosa MY, Elliot JH, Ndung'u T, Lewin SR, French MA, Carr WH.

AIDS. 2014 Mar 13;28(5):657-66. doi: 10.1097/QAD.0000000000000200.

13.

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.

Ziemssen T, Thomas K.

Ther Adv Neurol Disord. 2017 Oct;10(10):343-359. doi: 10.1177/1756285617722706. Epub 2017 Aug 4.

14.

Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs.

Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T, Bougras G, Muller WA, Moretta L, Münz C.

Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606-11. Epub 2004 Nov 9.

15.

Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation.

Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer L, La Cava A, Shi FD.

Ann Neurol. 2011 Apr;69(4):721-34. doi: 10.1002/ana.22339. Epub 2011 Mar 18.

16.

Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.

Gillard GO, Saenz SA, Huss DJ, Fontenot JD.

J Neuroimmunol. 2016 May 15;294:41-5. doi: 10.1016/j.jneuroim.2016.03.008. Epub 2016 Mar 29.

17.

Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells.

Münz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW.

Blood. 2005 Jan 1;105(1):266-73. Epub 2004 Aug 26.

18.

Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells.

Wimperis JZ, Niemeyer CM, Sieff CA, Mathey-Prevot B, Nathan DG, Arceci RJ.

Blood. 1989 Oct;74(5):1525-30.

19.

Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Freedman MS, Kaplan JM, Markovic-Plese S.

J Clin Cell Immunol. 2013 Jul 8;4(4). pii: 1000152.

20.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645

Supplemental Content

Support Center